Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.62 |
| ▸ | AKT1 | P31749 | 5/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.47 |
| ▸ | STK10 | O94804 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12277881 | 0.86 | PIK3CA (0.62) | PIK3CAMAP2K2CSNK1DCLK2CSNK1G2 | |
| SCHEMBL30440259 | 0.86 | PIK3CA (0.62) | PIK3CAMAP2K2CSNK1DCLK2CSNK1G2 | |
| SCHEMBL730195 | 0.84 | PIK3CA (0.84) | PIK3CAAKT1PIM1PIK3CDGAK | |
| SCHEMBL17833787 | 0.83 | PIK3CA (0.48) | PIK3CAGAKAAK1SLC22A12NCF1 | |
| SCHEMBL28140817 | 0.83 | ALK (0.49) | PIK3CASLC22A12NCF1HTT | |
| SCHEMBL730188 | 0.82 | PIK3CA (0.87) | PIK3CAAKT1PIM1PIK3CDGAK | |
| SCHEMBL732236 | 0.82 | PIK3CA (0.43) | PIK3CAAKT1PIM1PIK3CDGAK | |
| SCHEMBL12850664 | 0.79 | PIK3CA (0.62) | PIK3CAAKT1PIM1PIK3CDGAK | |
| SCHEMBL21964214 | 0.77 | PIK3CA (0.43) | PIK3CAAKT1SLC22A12NCF1CCNC | |
| SCHEMBL29245485 | 0.77 | PIK3CA (0.59) | PIK3CAAKT1PIM1PIK3CDGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| EP-2678016-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | INTELLIKINE LLC | 2016-03-31 | — | — | US | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2012116237-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20120165321-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-8138347-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2011022439-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20100168100-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-06-17 | — | — | US | disclosed |
| EP-2192902-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 8/4885IMPDH2 1698/4885 |
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | PIK3CA 13/4885AKT1 95/4885IMPDH2 3947/4885 |
| US-20100168100-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | PIK3CA 13/4885AKT1 95/4885IMPDH2 3947/4885 |
| US-20120165321-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885AKT1 66/4885IMPDH2 3224/4885 |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | MTOR, PIK3CA, AKT1 | PIK3CA 2/4885AKT1 3/4885IMPDH2 1959/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885AKT1 8/4885IMPDH2 1698/4885 |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885AKT1 66/4885IMPDH2 3224/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | PIK3CA 4/4885AKT1 10/4885IMPDH2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.